NREP
NEW REPRESENTATIVE AT IB RECEIVED
05/08/2023
Voltar para busca
Dado oficial do USPTO
AFFISORB
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
AFFISORB
ST13
US500000079027965Classe
1, 5, 10, 42
Pedido
79027965
Registro
3602579
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
51
Atualização mais recente
05/08/2023
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5, 10, 42
Data de depósito
08/06/2006
Data de registro
07/04/2009
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
13/11/2015
Última transação
16/03/2016
Escritório responsável
United States Patent and Trademark Office
Código da situação
709
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
CH
Examinador
BLANE, SUZANNE
Unidade examinadora
M50
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
AC Immune SA
Affiris AG
Affiris Forschungs- und Entwicklungs GmbH
Representantes
JULIE B. SEYLER ABELMAN, FRAYNE & SCHWAB
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 10Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Chemical preparations for use in medical researchscience and laboratories; biological preparations in the nature of molecules for use in medical researchscience and laboratories for purposes of researchanalysis and diagnosticsbiological reagents known as probes for detecting and analyzing molecules in proteins or nucleotide arrays
Classe 5
Pharmaceutical preparations designed to remove pathological molecules from the blood for therapy and prophylaxis of medical conditionsAlzheimer disease and arteriosclerosis and other cardio-vascular diseases; chemical preparations for pharmaceutical and medical purposespeptide based substances for use in the treatment of Alzheimer disease and arteriosclerosis and other cardio-vascular diseases; vaccinesdiagnostic preparations for medical purposeschemical reagents for medical and veterinary purposesfor treatment and diagnosis of Alzheimer disease and arteriosclerosis and other cardio-vascular diseases; chemical and biological substances for medical usefor Alzheimer disease and arteriosclerosis and other cardio-vascular diseases
Classe 10
Medical instruments and apparatus as well as replacement parts of the aforementioned goodsinstruments and apparatus used in blood analysis and for removing pathological molecules from the blood for use in therapy and prophylaxis of medical conditionsblood filtersblood component separation apparatus
Classe 42
Development of medical diagnostictherapy and test methodsconducing clinical trials and scientific investigations for medical purposesresearch in the field of chemical medicinepharmaceutics and bacteriology
Publicações
Histórico de despachos e eventos da marca no USPTO.
51 publicações encontradas
CHLD
CHANGE OF OWNER RECEIVED FROM IB
11/02/2022
NREP
NEW REPRESENTATIVE AT IB RECEIVED
01/11/2021
INNT
TOTAL INVALIDATION PROCESSED BY THE IB
21/04/2017
INTS
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
15/07/2016
INPC
INVALIDATION PROCESSED
15/07/2016
INTR
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
13/07/2016
RNWL
INTERNATIONAL REGISTRATION RENEWED
23/06/2016
C71T
CANCELLED SECTION 71
13/11/2015
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
11/01/2013
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
04/02/2011
FICS
FINAL DISPOSITION NOTICE SENT TO IB
22/07/2009
FIMP
FINAL DISPOSITION PROCESSED
22/07/2009
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
07/07/2009
R.PR
REGISTERED-PRINCIPAL REGISTER
07/04/2009
PUBO
PUBLISHED FOR OPPOSITION
20/01/2009
NPUB
NOTICE OF PUBLICATION
31/12/2008
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
16/12/2008
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
11/12/2008
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/10/2008
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/10/2008
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
10/10/2008
CNRT
NON-FINAL ACTION MAILED
17/07/2008
CNRT
NON-FINAL ACTION WRITTEN
16/07/2008
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
23/06/2008
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
23/06/2008
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
23/06/2008
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
28/03/2008
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
13/03/2008
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
13/03/2008
CNRT
NON-FINAL ACTION MAILED
22/01/2008
CNRT
NON-FINAL ACTION WRITTEN
19/01/2008
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
20/12/2007
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
20/12/2007
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
20/12/2007
CPRA
PRIORITY ACTION MAILED
22/06/2007
CPRA
PRIORITY ACTION WRITTEN
21/06/2007
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
01/06/2007
ACEC
AMENDMENT FROM APPLICANT ENTERED
30/05/2007
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
30/05/2007
ALIE
ASSIGNED TO LIE
30/05/2007
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
29/05/2007
PAPER RECEIVED
11/05/2007
RFNT
REFUSAL PROCESSED BY IB
08/12/2006
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
16/11/2006
RFRR
REFUSAL PROCESSED BY MPU
16/11/2006
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
16/11/2006
CNRT
NON-FINAL ACTION WRITTEN
15/11/2006
DOCK
ASSIGNED TO EXAMINER
08/11/2006
NWAP
NEW APPLICATION ENTERED
13/10/2006
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
12/10/2006
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace AFFISORB ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.